Baseline characteristics (safety set)
| Demographics . |
|---|
| Overall age (y), N = 66 |
| Median, 75 |
| Max-min, 47-88 |
| Demographics . |
|---|
| Overall age (y), N = 66 |
| Median, 75 |
| Max-min, 47-88 |
| Parameter . | Number of patients (N = 66) . | Proportion (%) . |
|---|---|---|
| Age categories (y) | ||
| ≥75 | 34 | 51.5 |
| 65-75 | 26 | 39.4 |
| 50-65 | 5 | 7.6 |
| <50 | 1 | 1.5 |
| Sex | ||
| Female | 28 | 42.4 |
| Male | 38 | 57.6 |
| Race | ||
| White | 54 | 81.8 |
| Black or African American | 5 | 7.6 |
| Unknown | 4 | 6.1 |
| Asian | 2 | 3 |
| Multiple | 1 | 1.5 |
| ECOG performance status | ||
| 0-1 | 40 | 60.6 |
| 2-3 | 26 | 39.4 |
| AML type | ||
| De novo | 40 | 60.6 |
| Secondary | 26 | 39.4 |
| Previous HMA therapy | ||
| Yes | 12 | 18.2 |
| No | 54 | 81.8 |
| Number of HMA courses | ||
| 0 | 54 | 81.8 |
| 1-2 | 1 | 1.5 |
| 6-10 | 4 | 6.1 |
| >10 | 7 | 10.6 |
| WBC counts | ||
| 10.0-49.9 × 109/L | 15 | 22.7 |
| <10.0 × 109/L | 51 | 77.3 |
| ELN 2017 risk group | ||
| Favorable | 9 | 13.9 |
| Intermediate | 15 | 22.7 |
| Adverse | 33 | 50 |
| Unknown | 9 | 13.6 |
| NPM1 mutation | ||
| Missing | 14 | 21.2 |
| No | 44 | 66.7 |
| Yes | 8 | 12.1 |
| FLT3 mutation | ||
| Missing | 10 | 15.2 |
| No | 50 | 75.8 |
| Yes | 6 (3 with low ITD, 1 high, and 2 IDT unknown) | 9.1 |
| TP53 mutation | ||
| Missing | 18 | 27.3 |
| No | 36 | 54.5 |
| Yes | 11 | 18.2 |
| Parameter . | Number of patients (N = 66) . | Proportion (%) . |
|---|---|---|
| Age categories (y) | ||
| ≥75 | 34 | 51.5 |
| 65-75 | 26 | 39.4 |
| 50-65 | 5 | 7.6 |
| <50 | 1 | 1.5 |
| Sex | ||
| Female | 28 | 42.4 |
| Male | 38 | 57.6 |
| Race | ||
| White | 54 | 81.8 |
| Black or African American | 5 | 7.6 |
| Unknown | 4 | 6.1 |
| Asian | 2 | 3 |
| Multiple | 1 | 1.5 |
| ECOG performance status | ||
| 0-1 | 40 | 60.6 |
| 2-3 | 26 | 39.4 |
| AML type | ||
| De novo | 40 | 60.6 |
| Secondary | 26 | 39.4 |
| Previous HMA therapy | ||
| Yes | 12 | 18.2 |
| No | 54 | 81.8 |
| Number of HMA courses | ||
| 0 | 54 | 81.8 |
| 1-2 | 1 | 1.5 |
| 6-10 | 4 | 6.1 |
| >10 | 7 | 10.6 |
| WBC counts | ||
| 10.0-49.9 × 109/L | 15 | 22.7 |
| <10.0 × 109/L | 51 | 77.3 |
| ELN 2017 risk group | ||
| Favorable | 9 | 13.9 |
| Intermediate | 15 | 22.7 |
| Adverse | 33 | 50 |
| Unknown | 9 | 13.6 |
| NPM1 mutation | ||
| Missing | 14 | 21.2 |
| No | 44 | 66.7 |
| Yes | 8 | 12.1 |
| FLT3 mutation | ||
| Missing | 10 | 15.2 |
| No | 50 | 75.8 |
| Yes | 6 (3 with low ITD, 1 high, and 2 IDT unknown) | 9.1 |
| TP53 mutation | ||
| Missing | 18 | 27.3 |
| No | 36 | 54.5 |
| Yes | 11 | 18.2 |
AML, acute myeloid leukemia; ECOG, Eastern Cooperative Oncology Group; ELN, European LeukemiaNet; FLT3, FMS-like receptor tyrosine kinase-3; HMA, hypomethylating agents; ITD, intertandem duplication; max, maximum; min, minimum; NPM1, nucleophosmin 1; TP53, tumor protein 53.